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Endogenous peroxynitrite modulates PGHS-1-dependent
thromboxane A2 formation and aggregation in human platelets
Abstract
Aggregation of activated platelets is considerably mediated by the autocrine action of thromboxane A2
(TxA2) which is formed in a prostaglandin endoperoxide H2 synthase-1 (PGHS-1 or COX-1)-dependent
manner. The activity of PGHS-1 can be stimulated by peroxides, an effect termed "peroxide tone", that
renders PGHS-1 the key regulatory enzyme in the formation of TxA2. Activated platelets release nitric
oxide (*NO) and superoxide (O*2) but their interactions with the prostanoid pathway have been
controversially discussed in platelet physiology and pathophysiology. The current study demonstrates
that endogenously formed peroxynitrite at nanomolar concentrations, originating from the interaction of
*NO and *O2, potently activated PGHS-1, which parallels TxA2 formation and aggregation in human
platelets. Inhibition of the endogenous formation of either *NO or O*2 resulted in a
concentration-dependent decline of PGHS-1 activity, TxA2 release, and aggregation. The concept of
peroxynitrite as modulator of TxA2 formation and aggregation explains the interaction of *NO and O*2
with the PGHS pathway and suggests a mechanism by which antioxidants can regulate
PGHS-1-dependent platelet aggregation. This may provide a molecular explanation for the clinically
observed hyperreactivity of platelets in high-risk patients and serve as a basis for novel therapeutic
interventions.
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Endogenous Peroxynitrite Modulates PGHS-1–Dependent 
Thromboxane A2 Formation and Aggregation in Human Platelets 
Abstract 
Aggregation of activated platelets is considerably mediated by the autocrine action of 
thromboxane A2 (TxA2) which is formed in a prostaglandin endoperoxide H2 synthase-1 
(PGHS-1 or COX-1) -dependent manner. The activity of PGHS-1 can be stimulated by 
peroxides, an effect termed “peroxide tone”, that renders PGHS-1 the key regulatory enzyme 
in the formation of TxA2. Activated platelets release nitric oxide (
•
NO) and superoxide (
•
O2
-
) 
but their interactions with the prostanoid pathway have been controversially discussed in 
platelet physiology and pathophysiology. 
The current study demonstrates that endogenously formed peroxynitrite at nanomolar 
concentrations, originating from the interaction of 
•
NO and 
•
O2
-
, potently activated PGHS-1, 
which parallels TxA2 formation and aggregation in human platelets. Inhibition of the 
endogenous formation of either 
•
NO or 
•
O2
-
 resulted in a concentration-dependent decline of 
PGHS-1 activity, TxA2 release, and aggregation. 
The concept of peroxynitrite as modulator of TxA2 formation and aggregation explains the 
interaction of 
•
NO and 
•
O2
-
 with the PGHS pathway and suggests a mechanism by which 
antioxidants can regulate PGHS-1-dependent platelet aggregation. This may provide a 
molecular explanation for the clinically observed hyperreactivity of platelets in high-risk 
patients and serve as a basis for novel therapeutic interventions. 
Keywords: 
Prostaglandin endoperoxide synthase, Peroxynitrite, Nitric oxide, Superoxide, Thromboxane 
A2, Platelets, Peroxide tone 
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Introduction 
Activation of platelets represents a key event not only in acute thrombosis but also under 
chronic pathophysiological conditions such as diabetes, atherosclerosis, or aging, all of which 
are associated with alterations in the intracellular redox state [1,2]. Chronic activation of 
platelets results in an increased risk of capillary plugging as well as in an increased systemic 
vascular tone. Thus, it is important to assess the influence of oxidants on platelet reactivity, as 
they may become a potential target for therapeutic strategies to prevent enhanced platelet 
activation [3]. 
Aggregation is considerably influenced by the autocrine prostanoid thromboxane A2 (TxA2) 
[4,5]. The key enzyme in the cascade of TxA2 formation, which leads to platelet aggregation 
and thrombus formation, is prostaglandin endoperoxide H2 synthase-1 (PGHS-1) also referred 
as cyclooxygenase-1 (COX-1), which can be eminently modulated by peroxides [6,7].
 
Peroxides or peroxynitrite [8,9] convert the resting PGHS-1 into its active form in which a 
ferric heme together with a neighboring tyrosine (Tyr)-residue are converted to a ferryl 
species and a Tyr-radical, respectively. The interaction of this Tyr-radical with the substrate 
arachidonic acid yields an arachidonyl radical, which is capable of interacting with molecular 
oxygen to form 15-hydroperoxy-prostaglandin-9,11,-endoperoxide (PGG2). In a second step, 
PGG2 is reduced by the peroxidase activity of the enzyme to finally form the 15-hydroxy 
derivative PGH2 [10,11]. PGH2 is the substrate for a variety of different terminal prostanoid 
synthases, among which thromboxane A2 (TxA2) synthase plays a crucial role in platelets [5]. 
The initiation and maintenance of the PGHS catalytic cycle by peroxides was termed 
“peroxide tone” [12]. Interestingly, the peroxide tone for the two PGHS isoenzymes was 
reported to be 21nM for PGHS-1 but only 2nM for PGHS-2 [13]. With some exceptions, 
inducible PGHS-2 is usually expressed under diverse pathological conditions, which are 
mostly associated with an increased formation of oxidants [14]. Unlike PGHS-2, PGHS-1 is 
constitutively expressed in both platelets and in numerous other cell types. Its considerably 
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higher peroxide threshold can therefore be regarded as an effective biological regulatory 
mechanism to prevent uncontrolled prostanoid synthesis under resting conditions. 
The key modulators of cellular redox regulation are nitric oxide (
•
NO) and superoxide (
•
O2
-
) 
as well as their derivatives [15,16]. Both radicals can rapidly react with each other, leading to 
the formation of peroxynitrite (ONOO
-
) [17]. Peroxynitrite is mostly known to exhibit 
detrimental effects such as the initiation of lipid peroxidation, nitration of aromatic 
compounds, or oxidative modifications of sulfhydryl residues [18-20]. Although rightly 
considered as a highly reactive oxidant at high concentrations, endogenously formed 
peroxynitrite in the nanomolar range can be an important mediator of cellular redox regulation 
[15,16]. 
While the constitutively expressed endothelial NO-synthase (eNOS) is generally considered 
as the major NOS isoform in platelets [21], the enzymatic source of 
•
O2
-
 formation remains 
less clearly defined. Besides other potential sources like mitochondria, xanthine oxidase or 
“uncoupled” eNOS, the NADPH-oxidase complex is currently accepted as the major 
generator of 
•
O2
-
 in agonist-stimuated platelets [22-24]. However, it should be emphasized 
that the relative contribution of these enzymes to the 
•
O2
-
 generation in platelets is highly 
dependent on the type of stimulus applied. 
Various groups demonstrated that besides the classical 
•
NO/cGMP pathway, platelet 
aggregation could be differentially modulated by reactive nitrogen and oxygen species [23-
33]. In particular for added ONOO
-
 or Sin-1, paradoxical effects were reported depending on 
the biological environment, such as platelet rich plasma compared to washed platelets, low or 
high concentrations added, or bolus addition of ONOO
-
 versus fluxes generated by Sin-1. 
ONOO
-
, as a highly reactive oxidant, is known to dictate the peroxide tone for PGHS 
isoenzymes in vitro and in cell culture systems. In in vitro experiments, ONOO
-
 was proven to 
activate PGHS at low nanomolar concentrations, whereas micromolar concentrations nitrated 
and inactivated the enzyme. Inactivation of platelet PGHS by high concentrations of ONOO
-
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was prevented by co-addition of arachidonic acid, which protects the active site Tyr-radical 
from nitration [26]. 
However, in the presence of plasma, protein thiols or GSH, low concentrations of ONOO
-
 (3-
100µM) caused the intermediate formation of S-nitrosothiols that decomposed into 
•
NO, 
reducing platelet activation and aggregation via the classical cGMP pathway. In contrast, in 
washed platelets ONOO
-
 diffuses almost undisturbed into platelets and can activate PGHS-1 
that increases TxA2 and aggregation. These effects need to be clearly separated from high 
nonphysiological (300-1000µM) additions of ONOO
-
, where undirected protein oxidation and 
inactivation occur altering platelet aggregation [30]. 
We present evidence that endogenously formed peroxynitrite is a regulator of PGHS-1 
activity and TxA2 formation, capable of altering platelet aggregation. This is supported by the 
notions that antioxidants and polyphenols [34-37] can influence TxA2 and platelet aggregation 
[36]. The proposed mechanism could provide a molecular explanation for the clinically 
observed hyperreactivity of platelets in various pathophysiological conditions such as 
diabetes, arteriosclerosis or the aging process. 
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Materials and Methods 
Materials - Sin-1, the active metabolite of molsidomine, xanthine oxidase (buttermilk), and 
apocynin were purchased from Calbiochem (Darmstadt, Germany). Ascorbic acid, γ-
tocopherol, glutathione (GSH), and hypoxanthine were from Sigma (St. Louis, MO, USA). 
Spermine-NONOate was from Cayman Chemicals (Ann Arbor, MI, USA) and 
14
C-labeled 
arachidonic acid was obtained from American Radiolabeled Chemicals (ARC) (St. Louis, 
MO, USA). 
Preparation of Platelets - Blood was collected from healthy volunteers between 20 and 30 
years of age at the Herz-Zentrum Bodensee, Kreuzlingen. The Institutional Review Board of 
the Kanton Thurgau, Switzerland, approved the protocol for blood collection. Volunteers 
abstained from taking any NSAID for at least two weeks before venipuncture. Platelet rich 
plasma (PRP) was obtained by centrifugation of whole blood at 100g for 15min. Washed 
platelets were obtained according to the protocol of Boulos et al. [26] with minor 
modifications. To avoid contamination with lymphocytes and erythrocytes, at least 5mm of 
the PRP fraction closest to the lymphocyte/erythrocyte fraction was discarded. To obtain 
plasma-free platelets, PRP was further centrifuged at 450xg for 15min and resuspended in 
5mM Hepes-buffer, pH 7.0 containing 140mM NaCl, 2mM KCl, 14mM NaHCO3, 5.5mM 
glucose and 1mM MgCl2. The moderate g-force has the disadvantage of losing relatively high 
amounts of platelets but allows gentle resuspension with minimal stimulation. Comparison 
between EDTA and citrate as anti-coagulants revealed no significant difference when A23187 
was used as a stimulus. Although EDTA complexes most of the extracellular Ca
2+
, gentle 
addition of Ca
2+
 to PRP had only marginal effects on the qualitative outcome of platelet 
aggregation or TxA2 release. This indicates that the release of Ca
2+
 from intracellular stores is 
mainly responsible for the observations made. 
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Aggregometry - Aggregation of PRP was performed at 37°C in glass cuvettes (Probe and Go, 
Endingen, Germany) with constant stirring at 700rpm in an Elvi 840 aggregometer from 
Logos (Milano, Italy). PRP was pretreated with the respective compounds for 20min at 37°C 
under constant shaking (200rpm). Shape change and aggregation were recorded. Using blood 
from the same donor, single sets of experiments were performed. A23187-induced changes in 
light transmission without addition of other compounds were defined as 100%. 
PGHS Activity - Activity of purified PGHS-1 from ram seminal vesicles and of intact platelets 
was detected as described previously [8]. Purified PGHS-1 from ram seminal vesicles was 
purchased from Cayman, Ann Arbor, MI. Contaminating peroxides were removed by addition 
of 5units glutathione (GSH)-peroxidase, 0.2mM GSH, 325units/100µl catalase to the enzyme 
(10units/100µl), which was incubated at 37°C with 100µM phenol and 0.1µg/100µl hematin 
in 0.1mM Tris-HCl, pH 8.0. The reaction was initiated by the addition of 
14
C-arachidonic acid 
(
14
C-AA) (10µM). After 10s, various compounds such as Sin-1 or H2O2 were added. The 
reaction was terminated after 2min by the addition of ethyl acetate/citric acid (2M) (30:1). 
PGHS activity in platelet rich plasma was detected by pretreatment with the various 
compounds for 20min at 37°C under constant shaking (200rpm). Platelets were washed (see 
preparation of platelets) and 200µl of washed platelets (0.5*10
8
/ml) were incubated for 5min 
with the same compounds as before at 37ºC. The reaction was initiated by the addition of 
5µM 
14
C-AA and 2µM A23187 and terminated after 15min by 1ml ethyl acetate/citric acid 
(2M) (30:1). After vigorous mixing of the phases for at least 1min, the organic phase (0.9ml) 
was extracted, evaporated to a residual volume of approximately 0.1ml, spotted by glass 
capillaries onto silica TLC plates (Silica 60, Merck, Darmstadt, Germany) and subjected to 
chromatography with the mobile phase consisting of ethyl acetate : 2,2,4-trimethylpentane : 
acetic acid : water (110 : 50 : 20 : 100). For detection and quantification, a PhosphorImager™ 
system from Molecular Dynamics (Sunnyvale, CA) was used. Quantification of purified 
PGHS-1 activity was performed by the detection of total PGHS metabolites. Platelet PGHS 
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activity was determined by quantification of TxA2 generation relative to unmetabolized 
14
C-
AA using ImageQuant™ software. 
Platelet treatment with authentic peroxynitrite – Authentic peroxynitrite was synthesized 
according to the method by Beckman and Koppenol [17], and the concentration was 
determined spectrophotometrically (ε302=1670M
-1
cm
-1
). Controls were performed with 
decomposed peroxynitrite. All working solutions were prepared in 1mM NaOH. Platelet rich 
plasma at 37˚C was vigorously mixed with peroxynitrite. After 2min platelets were subjected 
to aggregation and PGHS-activity measurements. 
Detection of Reactive Oxygen Species (ROS) - ROS formation was detected using the L-012-
enhanced chemiluminescence (Wako Chemicals, Neuss, Germany) in a thermostated Sirius 
Luminometer from Berthold Detection Systems (Pforzheim, Germany) at intervals of 5s. 
200µl of washed platelets (0.5*10
8
/ml) were preincubated with the respective reagents and 
100µM deferoxamine to prevent Fenton chemistry for 20min at 37°C under constant shaking 
at 200rpm. Before detection of chemiluminescence, L-012 (100µM) was incubated for 3min 
to allow equilibration before stimulation. A23187 (2µM) was then added, and 
chemiluminescence was expressed as percent of relative light units (RLU). Alternatively, 
dihydrorhodamine 123 (DHR123) (5µM) was added to platelets for 15min in the dark 
following fluorescence detection (485nm/538nm). 
•
NO-Detection - 
•
NO release by platelets was detected with a 
•
NO electrode (ami NO-700, 
Innovative Instruments, Quee Brooks Court, FL, USA). The electrode was calibrated every 
day with NaNO2 standards in 0.1M H2SO4 containing 100µM potassium iodide. For 
calibration of the instrument, the ∆-current between baseline and the peak after addition of 
NaNO2 was determined. 
Plasma-free platelets (0.5*10
8
/ml) were pretreated with apocynin, PEG-SOD, or L-NAME for 
20min at 37°C under constant shaking (200rpm). A total volume of 400µl was then 
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transferred to a glass cuvette, and 
•
NO release was detected under constant stirring at 700rpm 
in an Elvi 840 aggregometer (Logos, Milano, Italy) following the addition of 2µM A23187. 
Preparation of Peroxynitrite-treated Lipid Fractions of Platelets – Microsomes obtained from 
human platelets by standard procedures were treated 3 times with 500µM of authentic 
peroxynitrite. The membrane peroxide concentration in this solution was detected by the 
ferric thiocyanate assay. Briefly, 495µl of 4.5mM FeSO4 in 0.2M HCl and 495µl of 3% 
KSCN in MeOH were mixed immediatedly before the addition of 10µl sample. Absorbance 
was detected at 500nm (58440 M
-1
cm
-1
). 
Statistical Analysis - All data were expressed as mean ±SD of at least three independent 
experiments. Due to individual differences between different donors, single sets of 
experiments were performed with blood from the same preparation. One way ANOVA was 
used to determine the significance of differences. A probability value of p<0.05 was 
considered statistically significant. 
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Results 
In this study, we used the Ca
2+
-ionophore A23187 as the stimulus of choice because it allows 
the Ca
2+
-dependent activation not only of phospholipase A2, but also of eNOS in platelets. 
Under such conditions, prostaglandin endoperoxide synthase-1 (PGHS-1) becomes the rate-
limiting enzyme for TxA2 synthesis and TxA2-dependent aggregation. A23187-induced 
aggregation was inhibited by roughly 70% with indomethacin or aspirin, therefore suggesting 
that TxA2 is one of the dominating mediators of platelet aggregation (not shown). 
Sin-1 releases 
•
NO and 
•
O2
-
, which together form peroxynitrite in a nearly 1:1 stoichiometry. 
Given an approximate half-life time of 80-90min, this compound allows the generation of 
relatively steady state concentrations of peroxynitrite over the time-course of the experiments 
that are approximately 1*10
-4
 – 2*10
-4
 of the indicated Sin-1 concentrations (see [38] and 
Supplemental Material S1). While H2O2 even in the micromolar range triggered PGHS 
activity and aggregation only moderately (Fig. 1A) peroxynitrite was stimulatory when 
present at only nanomolar concentrations (Fig. 1B), an observation that implies that the 
potency of peroxynitrite is several orders of magnitude higher than that of H2O2. In contrast, 
after bolus additions of high concentrations of authentic peroxynitrite (Fig. 1C) a reduction in 
PGHS-1 activity and platelet aggregation can be observed, suggesting that in addition to other 
proteins PGHS becomes nitrated and inactivated. This has been observed for isolated PGHS 
[9] as well as in platelets [26]. 
Inhibition of the endogenous formation of peroxynitrite in activated platelets by the NADPH-
oxidase complex assembly inhibitor apocynin, PEG-SOD, the NOS-inhibitor L-NAME or 
uric acid, which besides 
•
NO and hydroxyl radicals also efficiently scavenges peroxynitrite, in 
each case lowered PGHS activity and platelet aggregation in a concentration-dependent 
manner (Fig. 2 A-D). These data support the concept that a major portion of the intracellular 
peroxide tone in platelets is provided by peroxynitrite. The activity of TxA2-synthase was not 
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affected by the different treatments employed in this work as detected by the conversion of 
14
C-PGH2 into 
14
C-TxA2 (data not shown). TxA2 released into the supernatant was measured 
as its stable hydration product TxB2 (Supplemental Material S2) and qualitatively revealed 
similar results as obtained in platelet aggregation and PGHS activity.  
Incubation of intact platelets with the peroxynitrite-donating compound Sin-1 could lead to 
the formation of various lipid oxidation products such as lipidhydroperoxides, nitrolipids or 
lipid alcohols that alternatively could influence PGHS activity by, for example, providing the 
peroxide tone via lipid hydroperoxides. However, treatment with increasing concentrations of 
ONOO
-
 treated lipid fractions caused minimal effects on PGHS activity and aggregation, and 
therefore lipid oxidation products appear as rather unlikely to account for the effects observed 
with Sin-1 in this study (Fig. 3). 
The luminol derivative L-012 and dihydrorhodamine 123 were used to estimate endogenous 
radical formation in activated platelets. L-012 demonstrated certain specificity for 
peroxynitrite, however it has to be mentioned that the detection of other radical species cannot 
be excluded. The inhibition of the L-012 chemiluminescence signal by uric acid, apocynin, or 
PEG-SOD but not by PEG-catalase strongly underscores the significance of endogenously 
formed peroxynitrite in A23187 activated platelets (Fig. 4). To test the contribution of 
•
NO 
and TxA2 in aggregation, platelets were treated with the guanylyl cyclase inhibitor ODQ, thus 
eliminating the direct anti-aggregatory properties of 
•
NO. ODQ only marginally increased 
platelet aggregation initiated by A23187 whereas the PGHS-inhibitor aspirin efficiently 
prevented platelet aggregation therefore supporting the role of pro-aggregatory TxA2 
(Supplement Material S3). 
To exclude the involvement of the cellular redox milieu on the effects described here, isolated 
and purified PGHS-1 enzyme was obtained to directly determine the efficacy of peroxynitrite 
as a physiological activator. The peroxynitrite-generating compound Sin-1 caused nearly a 
doubling of PGHS-1 activity in a concentration-dependent manner (Fig. 5A). To further 
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highlight the role of peroxynitrite in eliciting PGHS-1 activity, the enzyme was incubated 
with 1mM Sin-1 for full activation together with various concentrations of the anti-oxidants 
ascorbic acid or γ-tocopherol. In all cases, a concentration-dependent inhibition of PGHS-1 
activity was observed (not shown). When the peroxide tone was provided by separate 
generation of 
•
NO and 
•
O2
-
 using the 
•
NO-donor Spermine-NONOate and xanthine 
oxidase/hypoxanthine (100µM) as a source of 
•
O2
-
, increasing concentrations of peroxynitrite 
originating from the interaction of both radicals also yielded a concentration-dependent 
activation of PGHS-1 (Fig. 5B). From previous kinetic calculations it was concluded that the 
combinations of Spermine-NONOate and XO used in Fig. 5 generate nearly equal rates of 
•
NO and 
•
O2
-
 under the conditions employed (100µM Spermine-NONOate + 10mU/ml 
xanthine oxidase/hypoxanthine (100µM) ≈ 25nmol/l
-1
 s
-1
, respectively) [8] (Supplemental 
Material S1). 
To further assess the significance of equal fluxes of 
•
NO and 
•
O2
-
 for maximal peroxynitrite 
generation and PGHS activation, the impact of an imbalance between the two radicals was 
investigated. Excess of either 
•
NO or 
•
O2
-
 significantly impaired activation of isolated PGHS-
1 enzyme (Fig. 5C). This effect was only observed when peroxynitrite was applied to provide 
the peroxide tone. When other peroxides such as tert-butyl-OOH or H2O2 were used to 
activate the enzyme, 
•
NO or 
•
O2
-
 had no significant impact on PGHS-1 activity when added in 
the concentrations indicated (not shown). These observations suggest that excess of either 
•
NO or 
•
O2
-
 significantly decresed the levels of the PGHS-activator peroxynitrite. To 
investigate the physiological role of this interaction, intact activated platelets were treated 
with increasing fluxes of 
•
NO or 
•
O2
-
. At higher concentrations, a dose-dependent decline of 
PGHS activity in platelets was observed, suggesting an interaction of the added 
•
NO or 
•
O2
-
 
with endogenously formed peroxynitrite (Fig. 6). To further substantiate the interaction 
between endogenously formed 
•
NO and 
•
O2
-
, a 
•
NO-selective electrode was used. Stimulation 
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of washed platelets by 2µM A23187 resulted in an increase of 
•
NO in the supernatant that was 
maximal after roughly 20-30 seconds. Preincubation of platelets with the NADPH-oxidase 
inhibitor apocynin (Fig. 7A), or PEG-SOD (Fig. 7B) to limit the levels of free 
•
O2
-
, increased 
free 
•
NO. This indicates that significant amounts of 
•
NO formed by activated platelets directly 
interact with 
•
O2
-
 to form peroxynitrite. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
                                                Peroxide Tone in Platelets 14 
Discussion 
Concept of the “peroxide tone” 
The activation of prostaglandin endoperoxide H2 synthase (PGHS; COX) was summarized by 
the term “peroxide tone” [8,39,40], which describes that for the initiation and maintenance of 
the PGHS catalytic cycle, a steady presence of peroxides or peroxynitrite [9] is required. This 
unique property of the PGHS isoenzymes originates from their radical-based catalytic 
mechanism. It ultimately leads to the formation of a tyrosyl radical at the active site, which is 
necessary to activate the substrate arachidonic acid. Due to the reductive environment in a 
cell, this radical-based mechanism is continuously interrupted and requires a permanent 
reactivation by peroxides. Therefore the catalytic cycle of PGHS is of transient nature and 
dictated by intracellular peroxide levels. 
The peroxide tone for the inducible PGHS-2 was found to be 10-fold lower (2nM) than that 
for the constitutive PGHS-1 (21nM) [13]. Since PGHS-1 is expressed in most mammalian 
tissues, the higher peroxide tone for PGHS-1 could be considered an efficient means to 
prevent uncontrolled prostanoid formation under resting conditions. This is illustrated in 
human platelets, which constitutively express PGHS-1 and thromboxane A2 (TxA2)-synthase. 
TxA2 is a potent autocrine inducer of platelet aggregation and plays a vital role in rapid 
cessation of bleeding [41,42]. Under physiological conditions however, uncontrolled 
formation of TxA2 has to be strictly prevented in order to avoid thrombus formation in the 
vascular system. 
The data presented demonstrate and confirm previous literature reports [9,43] that 
peroxynitrite in the low nanomolar range acts as a potent endogenous activator of PGHS-1, 
which triggers TxA2 formation and aggregation in human platelets. Several reports indicate a 
direct impact of peroxynitrite on platelet function [29,33]. In most of these studies, authentic 
peroxynitrite in the upper micromolar range was used and led to protein nitration and reduced 
TxA2 generation [26]. Such high concentrations, however, are far above the levels of 
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endogenously formed reactive oxygen species. Furthermore, due to its short half-life time 
(t1/2≈1s), application of authentic peroxynitrite creates a very rapid peak and decay, which is 
not representative for the situation in vivo. In contrast to these reports [26,29,30,44], we used 
the peroxynitrite-generating compound Sin-1. Under the conditions applied in this work, 
1mM Sin-1 approximates relative steady-state peroxynitrite concentrations of about 100-
200nM over the time-course of the experiments. The proportion of the Sin-1-derived 
peroxynitrite reaching the target PGHS is likely to be considerably diminished compared to 
endogenously formed peroxynitrite on account to the closer proximity of endogenous sources 
to the target. Therefore, the peroxynitrite concentrations experimentally generated actually 
represent higher levels (peroxide tone of PGHS-1 ≈ 21nM) of peroxinitrite than the situation 
in vivo in order to saturate the peroxide tone. 
Control of platelet aggregation by 
•
NO – Is 
•
NO a promoter and inhibitor of aggregation at 
once?  
•
NO is well known for its role as anti-coagulant by the established increase in 
intracellular cGMP levels [45]. However, when A23187 was used as a stimulus, a modest 
proportion of the endogenously formed 
•
NO by platelet eNOS prevented aggregation, as 
proven by incubation with the guanylyl cyclase inhibitor ODQ. With respect to its anti-
aggregatory property, NOS inhibitors should promote aggregation rather than inhibit it. 
Radomski et al. [46] demonstrated that a 3-minute preincubaion with L-NMMA resulted in an 
increase in aggregation of stimulated platelets. We could successfully reproduce these 
findings (Supplemental Material S4). Nevertheless, some evidence exists suggesting that the 
anti-aggregatory role of platelet-derived 
•
NO was overestimated in the past. Freedman and 
coworkers demonstrated that 
•
NO has only moderate inhibitory properties on initial platelet 
activation but had profound impact on additional platelet recruitment to an existing thrombus 
[47]. To block the endogenous peroxynitrite-provided peroxide tone, a prolonged incubation 
time (≥20min) of either L-NAME or L-NMMA was necessary. Then, the TxA2-mediated 
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effects dominated over those directly evoked by endogenous 
•
NO (Supplemental Material 
S4). 
A second mechanism proposed by Moro et al. [29,48,49] contended that if peroxynitrite is 
added as a bolus at low micromolar concentrations to platelet rich plasma, plasma proteins 
and low molecular weight thiols might be converted into S-nitrosothiols [50]. These can 
liberate free 
•
NO and prevent platelet aggregation via the classical 
•
NO/cGMP-pathway. We 
could successfully reproduce these effects as shown in figure 1C. Other groups used washed 
platelets and treated them with peroxynitrite, which at low concentrations caused an increase 
in aggregation and TxA2 release, whereas high concentrations resulted in protein oxidation 
and nitration [9,26,30,44] that inhibited PGHS [9,26] and reduced aggregation [26]. Because 
Sin-1 generated nanomolar fluxes of peroxynitrite and platelets may be permeable for the 
compound, the S-nitrosothiol formation in plasma may play a minor role. In contrast to our 
findings, there are older reports that claim Sin-1 as an 
•
NO-donor that inhibits platelet 
aggregation [51-53] in a cGMP-dependent way. As shown in Fig. S1, the fluxes of Sin-1-
generated peroxynitrite must stabilize over the first 5min due to the complex chemistry of 
Sin-1 decomposition [50] and are therefore “only relatively steady state.” In the first few 
minutes Sin-1 may release relatively more 
•
NO than 
•
O2
-
 and increase cGMP. Accordingly, 
the very short incubation times between 30s and 2min [48,50,51,52] of Sin-1 with platelets 
used in these reports showing inhibition of aggregation by Sin-1 may not be sufficient to 
establish stable peroxynitrite fluxes in the experiment. 
A third mechanism of how 
•
NO can attenuate platelet aggregation is given by the complicated 
chemistry of 
•
NO in biological systems [17]. The generation of peroxynitrite is only maximal 
when 
•
NO and 
•
O2
–
 are generated in an equimolar ratio. An excess of either radical 
significantly decreases the levels of reactive peroxynitrite [54] and therefore reduces the 
peroxide tone and PGHS activity [8]. In accordance with these previous observations, the 
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addition of 
•
NO in excess of peroxynitrite significantly reduced PGHS activity in intact 
platelets. It has to be highlighted that the ratio between endogenously formed 
•
NO and 
•
O2
-
 in 
platelets is highly dependent on the stimulus applied. Agonist-dependent differences in the 
formation of 
•
NO and 
•
O2
-
 can have profound impact on PGHS activity and aggregation and 
can explain several contrary observations in literature with respect to the interaction with the 
PGHS pathway. Though 
•
NO was reported to attenuate PGHS activity by a direct reaction 
with the active site tyrosyl radical of the enzyme [43,55,56], nonphysiological concentrations 
of at least 1-2mM of free 
•
NO were required for this interaction, which renders this 
mechanism as very unlikely to occur in biological systems [57]. 
A second pathway to explain how 
•
NO could attenuate platelet aggregation is the recently 
discovered 
•
NO-dependent S-glutathiolation and activation of the Ca
2+
-pump SERCA, which 
lowers the levels of [Ca
2+
]i [58]. Nevertheless, in the current study, effects of 
•
NO on SERCA 
activity can be neglected, since the potent Ca
2+
-ionophore A23187 was used to obtain 
maximal activation of the eicosanoid-signaling cascade. We have chosen the Ca
2+
-ionophore 
A23187 at a relatively high concentration (2µM) to cause maximal platelet activation. With 
respect to the questions addressed in this work, an increase of [Ca
2+
]i was mainly required for 
the PLA2-catalyzed release of AA and the activation of eNOS. By comparing the effects of 
complexation and re-addition of extracellular Ca
2+
 to the platelet suspension (data not shown), 
we observed that intracellular stores were the major source of Ca
2+
. 
Can other peroxides provide the peroxide tone? 
Several publications previously indicated an involvement of H2O2 on TxA2 production and 
platelet aggregation [25,27]. In these reports, activation at low concentrations of H2O2 was 
followed by an inhibition at higher concentrations [27]. Although H2O2 can undoubtedly be 
involved in generating the intracellular peroxide tone, the fact that peroxynitrite is about 500-
1000 times more potent than H2O2 in activating PGHS in platelets, makes peroxynitrite the 
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more likely endogenously relevant candidate. Furthermore, application of PEG-catalase 
revealed no significant impact on platelet aggregation, PGHS activity, or TxB2 formation 
under the experimental conditions employed in this work (Supplemental Material S5). The 
incubation of platelets with the peroxynitrite-donor Sin-1 could alternatively lead to the 
formation of lipid oxidation products such as nitrolipids, lipid hydroperoxides or lipid 
alcohols, which in turn could serve as modulators of PGHS-activity. Human platelet 
membrane fractions were therefore treated with peroxynitrite. Incubation of intact platelets 
with these lipid fractions had no effect on PGHS activity and aggregation. From the 
observations made in this work in human platelets as well as in other cell types like vascular 
endothelial and smooth muscle cells [8,34,40,43,59], peroxynitrite appears to be one of the 
most potent endogenously formed regulators of PGHS activity and prostanoid synthesis in 
mammalian cells. 
Interference of antioxidants with the peroxide tone 
The concept of the peroxynitrite-mediated activation of PGHS-1 and ultimately TxA2 
synthesis by platelets also gives an explanation for several previous studies on the influence 
of antioxidants on platelet aggregation. Uric acid, vitamin C, and vitamin E, in particular γ-
tocopherol, could efficiently scavenge peroxynitrite and attenuate platelet aggregation. For 
vitamin E, PGHS-independent effects on platelet aggregation were shown [60]. However, we 
could not observe additional effects of γ-tocopherol on platelet aggregation after inhibition of 
TxA2 synthesis by aspirin thus strongly suggesting a direct influence of antioxidants on the 
cellular peroxide tone. The concept of antioxidants as scavengers of peroxynitrite and their 
impact on PGHS activity [35,36] is not only limited to the situation in platelets but was, for 
example, also demonstrated in macrophages from old mice [34] and can certainly be 
considered as a general mechanism taking place in nearly all cell types [8,9,26,40,43,59]. 
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Conclusions  
The vascular system can be regarded as a perfect example of a biological yin-yang system in 
which anti-aggregatory PGI2 from the endothelium and pro-aggregatory TxA2 from platelets 
represent a well-balanced system of vasoactive eicosanoids. Under physiological conditions, a 
significant portion of PGI2 is formed in a PGHS-2-dependent manner, although the precise 
anatomic origin of PGI2 is so far only poorly defined [61]. Due to the 10-fold lower 
requirement for peroxides to activate PGHS-2, the “peroxide tone” would rather favor the 
formation of anti-aggregatory PGI2 under normal conditions, whereas the formation of TxA2 
would be suppressed. However, pathophysiological conditions are associated with an 
increased oxidant formation. Such circumstances would favor the inactivation of PGI2-
synthase by nitration in the endothelium and in parallel would enhance the formation of TxA2 
by platelets [20]. With the concept of peroxynitrite as an activator of PGHS-1-dependent 
TxA2 formation and aggregation, previous clinical observations made with different 
antioxidants might now be explained on the molecular level. A pharmacological modification 
of the “net effect” of peroxynitrite in the vasculature may eventually become a novel strategy 
to combat chronic pathophysiological situations like diabetes, atherosclerosis or aging. 
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List of Abbreviations 
 
DHR 123 –Dihydrorhodamine 123 
GSH- Glutathione 
H2O2- Hydrogen Peroxide 
•
NO- Nitric oxide 
NOS- Nitric Oxide Synthase 
•
O2
-
 -Superoxide 
ODQ- 1H[1,2,4] Oxadiazolo[4,3]Quinoxalin-1-one 
ONOO
-
 -Peroxynitrite 
PEG-SOD- Polyethylene Glycol Superoxide Dismutase 
PGHS; COX- Prostaglandin Endoperoxide H2 Synthase 
PGI2- Prostacyclin 
PRP- Platelet Rich Plasma 
TxA2- Thromboxane A2 
XO- Xanthine Oxidase 
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Figure Legends 
Fig. 1. Activation of PGHS and aggregation by peroxynitrite. Platelet rich plasma was 
preincubated with hydrogen peroxide (H2O2, 1-100µM) (A), Sin-1 (10-1000µM) (B) for 
20min at 37ºC under constant shaking (200rpm). Aggregation was triggered after 2min by 
addition of A23187 (2µM). Treatment with authentic peroxynitrite (1-100µM) (C) was 
performed under vigorous mixing and aggregation and PGHS-activity was measured after 
2min by addition of A23187 (2µM). H2O2 resulted in marginal stimulation (A) in response to 
A23187 (2µM), whereas the peroxynitrite-generating compound Sin-1 (B) significantly 
elevated platelet PGHS turnover and aggregation. Relative steady-state concentrations of 
peroxynitrite over the time-course of the experiments released by Sin-1 under the conditions 
employed were in the nanomolar range. (C) Treatment of platelets with authentic 
peroxynitrite caused a concentration-dependent inhibition of platelet aggregation due to the 
formation of S-nitrosothiols with serum proteins and low molecular weight thiols as reported 
by Moro et al. [49]. Values are means ± SD (n=6) (*P < 0.05). 
 
Fig. 2. Inhibition of endogenous peroxynitrite formation. Platelet rich plasma was treated 
with the peroxynitrite-scavenger uric acid (10-1000µM) (A), the NO-synthase inhibitor L-
NAME (10-1000µM) (B), PEG-SOD (50-200u/ml) (C), or the NADPH oxidase inhibitor 
apocynin (10-1000µM) (D) for 20min at 37ºC under constant shaking (200rpm) in order to 
prevent the endogenous formation of peroxynitrite. Inhibition of either 
•
NO or 
•
O2
-
 formation 
as precursors of peroxynitrite, resulted in a concentration-dependent decline of PGHS activity 
and aggregation. Values are means ± SD (n=6) (*P < 0.05) 
 
Fig. 3. Influence of peroxynitrite-treated lipid fractions of platelets on PGHS activity 
and platelet aggregation. Incubation of platelets with Sin-1 can lead to the formation of e.g. 
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lipid hydroperoxides, nitrolipids and lipid alcohols, which may serve as alternative 
modulators of PGHS to peroxynitrite. To test this hypothesis, platelet membrane fractions 
were treated with high concentrations (500µM) of authentic peroxynitrite. Incubation of 
platelet rich plasma with increasing concentrations of these lipid fractions (concentrations 
from 1-100nM represent the peroxide content measured with the ferric thiocyanate assay) had 
no significant effect on PGHS activity and aggregation. Values are means ± SD (n=6) (*P < 
0.05). 
 
Fig. 4. Detection of reactive oxygen species. Platelet rich plasma was preincubated for 
20min at 37ºC under constant shaking with peroxynitrite-scavenger uric acid (10-1000µM) 
(A), the NO-synthase inhibitor L-NAME (10-1000µM) (B), PEG-SOD (50-200u/ml) (C), or 
the NADPH oxidase inhibitor apocynin (10-1000µM) (D). Data represent A23187 (2µM) 
stimulated L-012-enhanced (100µM) chemiluminescence of washed platelets integrated over 
a time period of 1min after stimulation, or the cumulative fluorescent signal of oxidized 
dihydrorhodamine 123 (DHR 123, 5µM). In a concentration-dependent manner, ROS-
generated L-012 chemiluminescence or DHR 123 fluorescence was markedly decreased by 
uric acid (A), apocynin (B), and PEG-SOD (C) but not by PEG-catalase (D). DHR 123 
showed higher background levels.Values are means ± SD (n=6) (*P < 0.05) 
 
Fig. 5. Purified PGHS-1 is activated by peroxynitrite. To exclude an interaction with the 
cellular redox milieu, purified PGHS-1 enzyme (10U) was treated at 37ºC with increasing 
fluxes of peroxynitrite generated by either Sin-1 (A) or a system with spermine-NONOate/ 
xanthine oxidase/ hypoxanthine [100µM] (B+C). A concentration-dependent increase in 
activity was observed with Sin-1 (A) (10-1000µM). Sin-1 generates nitric oxide (
•
NO) and 
superoxide (
•
O2
-
) in a 1:1 ratio to yield peroxynitrite. Release of 
•
NO by spermine-NONOate 
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(50-500µM) and 
•
O2
-
 by xanthine oxidase (5-50mU/ml)/ hypoxanthine [100µM], resulted in 
an increased PGHS-1 activity (B). The combinations were chosen to yield a ≈ 1:1 ratio under 
the conditions employed. Activation of PGHS-1 proved to be maximal only in the presence of 
equal fluxes of 
•
NO and 
•
O2
-
 while excess of either radical significantly declined enzymatic 
turnover (C) (xanthine oxidase, 100mU/ml; hypoxanthine, 100µM; spermine-NONOate, 0.1-
5mM). Values are means ± SD (n=3) (*P < 0.05). 
 
Fig. 6. Interaction of 
•
NO or 
•
O2
-
 with endogenous peroxynitrite. Treatment of platelet 
rich plasma at 37ºC under constant shaking (200rpm) with either nitric oxide (
•
NO) (A) 
(spermine-NONOate 0.1-100µM) or superoxide (
•
O2
-
) generating systems (B) (xanthine 
oxidase/hypoxanthine [100µM], 0.1-100mU/ml) resulted in a decline of PGHS activity, 
suggesting an interaction of 
•
NO or 
•
O2
-
 with endogenously formed peroxynitrite. The 
moderate increase observed with 0.1µM spermine-NONOate suggests a slight excess of 
endogenously formed 
•
O2
-
 over 
•
NO. Platelet rich plasma was incubated with Sin-1 [1mM] or 
H2O2 [100µM] at 37ºC for 20min under constant shaking (200rpm) and increasing 
concentrations of uric acid (10-1000µM) (C). Uric acid blocks concentration-dependently the 
activation of platelet PGHS-1 by Sin-1 but the effects of H2O2. Values are means ± SD (n=6) 
(*P < 0.05; # P < 0.05). 
 
Fig. 7. 
•
NO-release by platelets. Washed platelets were preincubated with apocynin (A) (10-
1000µM), PEG-SOD (100U/ml) (B), or L-NAME (100µM) (B) for 20min at 37ºC under 
constant stirring (700rpm). Nitric oxide (
•
NO) was detected with an NO-electrode following 
stimulation with 2µM A23187. Inhibition of endogenous Superoxide (
•
O2
–
) formation 
increased and prolonged the release of 
•
NO, which suggests that endogenously formed 
•
NO 
instantly interacts with 
•
O2
-
 to form peroxynitrite. Values are means ± SD (n=5) (*P < 0.05) 
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Fig. 8. Stimulation of TxA2 release by peroxynitrite. Peroxynitrite originates from the 
interaction of nitric oxide (
•
NO) with superoxide (
•
O2
-
) and stimulates PGHS-1, leading to an 
increased formation of pro-aggregatory thromboxane A2 (TxA2). 
•
NO can directly exert anti-
aggregatory properties. The balance between TxA2- and 
•
NO-mediated effects should 
therefore be highly dependent on the formation of 
•
O2
-
. Activation of PGHS by peroxides is 
initiated by the oxidation of the ferric (Fe
3+
) resting enzyme to a protoporphyrin cation radical 
([Fe
4+
=O]
•+
). An intramolecular electron transfer yields a tyrosyl radical (Tyr
•
) at the active 
site of the cyclooxygenase domain and an oxoferryl heme (Fe
4+
=O) at the peroxidase site. 
Cellular reductants can inhibit the cycle by reverting the enzyme back to its resting state, 
which requires the permanent presence of peroxides. This effect is termed “peroxide tone”. 
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